Mark D. Pegram, MD
Breast cancer treatment has evolved dramatically over the past 2 decades, said Mark D. Pegram, MD, and several approaches are emerging for those with HER2-positive metastatic disease in the form of new antibody-drug conjugates (ADCs) and small molecule inhibitors.
, Pegram highlighted data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and shed light on emerging agents that are showing promise in the pipeline.
OncLive: What have been the most exciting data in the HER2-positive breast cancer space?
: There has never been a more exciting time to be in the area of clinical research and clinical investigation for HER2-positive breast cancer. Some might say that there is not much work left to be done, particularly in early stages of HER2-positive breast cancer, because of the results of the adjuvant trastuzumab plus chemotherapy trials. These studies, from over a decade ago, were so spectacular that some people feel the “heavy lifting” is over.
... to read the full story